BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 29312569)

  • 1. Metformin improves nonalcoholic fatty liver disease in obese mice via down-regulation of apolipoprotein A5 as part of the AMPK/LXRα signaling pathway.
    Lin MJ; Dai W; Scott MJ; Li R; Zhang YQ; Yang Y; Chen LZ; Huang XS
    Oncotarget; 2017 Dec; 8(65):108802-108809. PubMed ID: 29312569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Metformin reduces plasma triglycerides in ob/ob obese mice via inhibiting the hepatic apoA5 expression].
    Huang X; Li R; Chen L; Dai W
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2017 Dec; 42(12):1389-1394. PubMed ID: 29317579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metformin ameliorates obesity-associated hypertriglyceridemia in mice partly through the apolipoprotein A5 pathway.
    Li R; Chen LZ; Zhao W; Zhao SP; Huang XS
    Biochem Biophys Res Commun; 2016 Sep; 478(3):1173-8. PubMed ID: 27544029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Olanzapine causes non-alcoholic fatty liver disease via inhibiting the secretion of apolipoprotein A5.
    Li R; Zhu W; Huang P; Ding C; Tang Y; Lian P; Huang X
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2022 Jun; 47(6):730-738. PubMed ID: 35837772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of apolipoprotein A5 in non-alcoholic fatty liver disease.
    Ress C; Moschen AR; Sausgruber N; Tschoner A; Graziadei I; Weiss H; Schgoer W; Ebenbichler CF; Konrad RJ; Patsch JR; Tilg H; Kaser S
    Gut; 2011 Jul; 60(7):985-91. PubMed ID: 21339203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Olanzapine leads to nonalcoholic fatty liver disease through the apolipoprotein A5 pathway.
    Li R; Zhu W; Huang P; Yang Y; Luo F; Dai W; Shen L; Pei W; Huang X
    Biomed Pharmacother; 2021 Sep; 141():111803. PubMed ID: 34146854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metformin inhibits hepatic gluconeogenesis through AMP-activated protein kinase-dependent regulation of the orphan nuclear receptor SHP.
    Kim YD; Park KG; Lee YS; Park YY; Kim DK; Nedumaran B; Jang WG; Cho WJ; Ha J; Lee IK; Lee CH; Choi HS
    Diabetes; 2008 Feb; 57(2):306-14. PubMed ID: 17909097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methionine restriction prevents the progression of hepatic steatosis in leptin-deficient obese mice.
    Malloy VL; Perrone CE; Mattocks DA; Ables GP; Caliendo NS; Orentreich DS; Orentreich N
    Metabolism; 2013 Nov; 62(11):1651-61. PubMed ID: 23928105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metformin alleviates hepatosteatosis by restoring SIRT1-mediated autophagy induction via an AMP-activated protein kinase-independent pathway.
    Song YM; Lee YH; Kim JW; Ham DS; Kang ES; Cha BS; Lee HC; Lee BW
    Autophagy; 2015; 11(1):46-59. PubMed ID: 25484077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiotrophin-1 eliminates hepatic steatosis in obese mice by mechanisms involving AMPK activation.
    Castaño D; Larequi E; Belza I; Astudillo AM; Martínez-Ansó E; Balsinde J; Argemi J; Aragon T; Moreno-Aliaga MJ; Muntane J; Prieto J; Bustos M
    J Hepatol; 2014 May; 60(5):1017-25. PubMed ID: 24362075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retinoic acid receptor-related orphan receptor α-induced activation of adenosine monophosphate-activated protein kinase results in attenuation of hepatic steatosis.
    Kim EJ; Yoon YS; Hong S; Son HY; Na TY; Lee MH; Kang HJ; Park J; Cho WJ; Kim SG; Koo SH; Park HG; Lee MO
    Hepatology; 2012 May; 55(5):1379-88. PubMed ID: 22183856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased apolipoprotein A5 expression in human and rat non-alcoholic fatty livers.
    Feng Q; Baker SS; Liu W; Arbizu RA; Aljomah G; Khatib M; Nugent CA; Baker RD; Forte TM; Hu Y; Zhu L
    Pathology; 2015 Jun; 47(4):341-8. PubMed ID: 25938357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current biochemical studies of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis suggest a new therapeutic approach.
    Hookman P; Barkin JS
    Am J Gastroenterol; 2003 Sep; 98(9):2093-7. PubMed ID: 14499793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nectandrin B, a lignan isolated from nutmeg, inhibits liver X receptor-α-induced hepatic lipogenesis through AMP-activated protein kinase activation.
    Choi du G; Kim EK; Yang JW; Song JS; Kim YM
    Pharmazie; 2015 Nov; 70(11):733-9. PubMed ID: 26790190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AMP-kinase pathway is involved in tumor necrosis factor alpha-induced lipid accumulation in human hepatoma cells.
    Lv Q; Zhen Q; Liu L; Gao R; Yang S; Zhou H; Goswami R; Li Q
    Life Sci; 2015 Jun; 131():23-9. PubMed ID: 25817233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monascin and ankaflavin act as natural AMPK activators with PPARα agonist activity to down-regulate nonalcoholic steatohepatitis in high-fat diet-fed C57BL/6 mice.
    Hsu WH; Chen TH; Lee BH; Hsu YW; Pan TM
    Food Chem Toxicol; 2014 Feb; 64():94-103. PubMed ID: 24275089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of adenosine monophosphate-activated protein kinase-p70 ribosomal S6 kinase-1 pathway in repression of liver X receptor-alpha-dependent lipogenic gene induction and hepatic steatosis by a novel class of dithiolethiones.
    Hwahng SH; Ki SH; Bae EJ; Kim HE; Kim SG
    Hepatology; 2009 Jun; 49(6):1913-25. PubMed ID: 19378344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Leptin administration restores the altered adipose and hepatic expression of aquaglyceroporins improving the non-alcoholic fatty liver of ob/ob mice.
    Rodríguez A; Moreno NR; Balaguer I; Méndez-Giménez L; Becerril S; Catalán V; Gómez-Ambrosi J; Portincasa P; Calamita G; Soveral G; Malagón MM; Frühbeck G
    Sci Rep; 2015 Jul; 5():12067. PubMed ID: 26159457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Yhhu981, a novel compound, stimulates fatty acid oxidation via the activation of AMPK and ameliorates lipid metabolism disorder in ob/ob mice.
    Zeng HL; Huang SL; Xie FC; Zeng LM; Hu YH; Leng Y
    Acta Pharmacol Sin; 2015 Mar; 36(3):343-52. PubMed ID: 25732571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Xuezhikang contributes to greater triglyceride reduction than simvastatin in hypertriglyceridemia rats by up-regulating apolipoprotein A5 via the PPARα signaling pathway.
    Zhao SP; Li R; Dai W; Yu BL; Chen LZ; Huang XS
    PLoS One; 2017; 12(9):e0184949. PubMed ID: 28934253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.